Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canadian user fees

This article was originally published in The Rose Sheet

Executive Summary

Canadian Cosmetic, Toiletry and Fragrance Association (CCTFA) expects that recently announced user fees for drugs will eventually be extended to cosmetics as well. CCTFA is working in conjunction with the Nonprescription Drug Manufacturers Association and the Canadian Drug Manufacturers Association to present the Canadian Drugs Directorate with a combined industry response to user fees. The Drugs Directorate recently announced that it plans to begin levying user fees for the "authority to market drugs." Scheduled to go into effect in late 1994 or early 1995, the fees will translate to $500 per OTC drug and $1000 per prescription drug. Charges to be established at later dates include fees for the manufacture, import or distribution of drug products, as well as for drug evaluation, file maintenance and adverse drug reaction monitoring

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel